Should Weakness in Zhejiang Gongdong Medical Technology Co., Ltd.'s (SHSE:605369) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Should Weakness in Zhejiang Gongdong Medical Technology Co., Ltd.'s (SHSE:605369) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Zhejiang Gongdong Medical Technology (SHSE:605369) has had a rough three months with its share price down 28%. However, stock prices are usually driven by a company's financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Zhejiang Gongdong Medical Technology's ROE in this article.
浙江共东医疗科技(上海证券交易所代码:605369)经历了艰难的三个月,其股价下跌了28%。但是,从长远来看,股票价格通常由公司的财务状况驱动,在这种情况下,这看起来相当可观。具体而言,我们决定在本文中研究浙江共东医疗科技的投资回报率。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
投资回报率或股本回报率是评估公司如何有效地从股东那里获得投资回报的有用工具。简而言之,它衡量公司相对于股东权益的盈利能力。
How To Calculate Return On Equity?
如何计算股本回报率?
The formula for ROE is:
ROE 的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营业务)÷ 股东权益
So, based on the above formula, the ROE for Zhejiang Gongdong Medical Technology is:
因此,根据上述公式,浙江工东医疗科技的投资回报率为:
6.5% = CN¥106m ÷ CN¥1.6b (Based on the trailing twelve months to September 2023).
6.5% = 1.06亿元人民币 ÷ 16亿元人民币(基于截至2023年9月的过去十二个月)。
The 'return' is the yearly profit. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.07 in profit.
“回报” 是每年的利润。将其概念化的一种方法是,公司每拥有1元人民币的股东资本,公司就会获得0.07元的利润。
What Has ROE Got To Do With Earnings Growth?
投资回报率与收益增长有什么关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
我们已经确定,投资回报率是衡量公司未来收益的有效盈利指标。然后,我们能够评估公司的收益增长潜力,具体取决于公司对这些利润进行再投资或 “保留” 了多少及其有效性。一般而言,在其他条件相同的情况下,股本回报率和利润留存率高的公司的增长率要高于不具有这些属性的公司。
Zhejiang Gongdong Medical Technology's Earnings Growth And 6.5% ROE
浙江共东医疗科技的收益增长和6.5%的投资回报率
On the face of it, Zhejiang Gongdong Medical Technology's ROE is not much to talk about. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 9.3%. However, the moderate 14% net income growth seen by Zhejiang Gongdong Medical Technology over the past five years is definitely a positive. So, there might be other aspects that are positively influencing the company's earnings growth. Such as - high earnings retention or an efficient management in place.
从表面上看,浙江共东医疗科技的投资回报率没什么好谈的。然后,我们将该公司的投资回报率与整个行业进行了比较,但对投资回报率低于行业平均水平的9.3%感到失望。但是,在过去五年中,浙江共东医疗科技实现了14%的温和净收入增长,这绝对是积极的。因此,可能还有其他方面对公司的收益增长产生积极影响。例如——高收益留存率或实行高效管理。
Next, on comparing Zhejiang Gongdong Medical Technology's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 16% over the last few years.
接下来,在将浙江工东医疗科技的净收入增长与该行业的净收入增长进行比较时,我们发现该公司报告的增长与过去几年16%的行业平均增长率相似。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240202/0-69b765c511d07f26875e681101407f88-0-3e27ee9a8d288bd98a77f47473368321.png/big)
Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Zhejiang Gongdong Medical Technology fairly valued compared to other companies? These 3 valuation measures might help you decide.
收益增长是股票估值的重要因素。对于投资者来说,重要的是要知道市场是否对公司的预期收益增长(或下降)进行了定价。通过这样做,他们将知道股票是走向清澈的蓝色海水还是沼泽水域在等着呢。与其他公司相比,浙江共东医疗科技的估值是否合理?这3种估值指标可能会帮助您做出决定。
Is Zhejiang Gongdong Medical Technology Efficiently Re-investing Its Profits?
浙江共东医疗科技是否有效地将其利润再投资?
Zhejiang Gongdong Medical Technology has a three-year median payout ratio of 45%, which implies that it retains the remaining 55% of its profits. This suggests that its dividend is well covered, and given the decent growth seen by the company, it looks like management is reinvesting its earnings efficiently.
浙江共东医疗科技的三年派息率中位数为45%,这意味着它保留了剩余的55%的利润。这表明其股息覆盖范围良好,鉴于该公司的可观增长,管理层似乎正在有效地对其收益进行再投资。
Moreover, Zhejiang Gongdong Medical Technology is determined to keep sharing its profits with shareholders which we infer from its long history of three years of paying a dividend.
此外,浙江工东医疗科技决心继续与股东分享利润,这是我们从其三年派息的长期历史中推断出来的。
Conclusion
结论
Overall, we feel that Zhejiang Gongdong Medical Technology certainly does have some positive factors to consider. Even in spite of the low rate of return, the company has posted impressive earnings growth as a result of reinvesting heavily into its business. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
总体而言,我们认为浙江共东医疗科技确实有一些积极因素需要考虑。尽管回报率很低,但由于对业务进行了大量再投资,该公司的收益增长令人印象深刻。话虽如此,最新的行业分析师预测显示,该公司的收益有望加速。要详细了解分析师对公司的最新预测,请查看该公司的分析师预测的可视化。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。